Last reviewed · How we verify
NCT05369078
Safety, Tolerance and Pharmacokinetics of THR-1442 in Chinese Healthy Subjects
Phase 1 trial testing THR-1442 20mg Single dose in T2DM (Type 2 Diabetes Mellitus) in 16 participants. Status unknown.
31 May 2022
Quick facts
| Lead sponsor | Newsoara Biopharma Co., Ltd. |
|---|---|
| Phase | Phase 1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 16 |
| Start date | 1 December 2021 |
| Primary completion | 31 May 2022 |
| Estimated completion | 31 May 2022 |
| Sites | 1 location across China |
Drugs / interventions tested
- THR-1442 20mg Single dose — full drug profile →
- THR-1442 20mg Multiple dose group — full drug profile →
Conditions studied
- T2DM (Type 2 Diabetes Mellitus) — all drugs for T2DM (Type 2 Diabetes Mellitus) →
Sponsor
Newsoara Biopharma Co., Ltd. — full company profile →
Who can join
Adults 18 to 45, any sex, with T2DM (Type 2 Diabetes Mellitus). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study was to investigate Safety, tolerability and pharmacokinetics in Chinese healthy subjects.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05369078
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for T2DM (Type 2 Diabetes Mellitus)
Currently open trials in the same condition.
- NCT07314684 — GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM · Phase 4 · recruiting
- NCT07005362 — Fitbit and AI Chatbot in Sedentary Primary Care Patients With T2D · recruiting
- NCT07244003 — Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control · Phase 4 · recruiting
- NCT07172997 — Non-Invasive MASLD Diagnosis & T2D Remission Biomarkers · active not recruiting
- NCT06094491 — Virtual Diabetes Group Visits Across Health Systems · Phase 2 · active not recruiting
Other Newsoara Biopharma Co., Ltd. trials
Trials by the same sponsor.
- NCT06218940 — HY1272 in Patients With Locally Advanced or Metastatic Solid Tumors or Locally Advanced or Metastatic EGFRm+ NSCLC · Phase 1 · not yet recruiting
- NCT06584058 — HPP737 Substance Balance Study in Human · NA · not yet recruiting
- NCT05159882 — Safety and Efficacy of THR-1442 Compared to Dapagliflozin as Add-on Therapy to Metformin in T2DM · Phase 3 · unknown
- NCT04714294 — Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers · Phase 1 · unknown
- NCT05056935 — Study to Evaluate LB1148 for Return of Gastrointestinal Function, Decrease Post-Operative Ileus · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05369078 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Newsoara Biopharma Co., Ltd.
- Last refreshed: 11 May 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05369078.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing